EA-7425 HESPER, Health Services and Performance Research, université de Lyon, 69003 Lyon, France; Service pharmaceutique, hôpital des Charpennes, hospices civils de Lyon, 69100 Lyon, France; Université Lyon 1, 69000 Lyon, France.
Université Lyon 1, 69000 Lyon, France.
Ann Pharm Fr. 2020 May;78(3):199-205. doi: 10.1016/j.pharma.2019.12.002. Epub 2019 Dec 16.
To explore caregiver, pharmacist and pharmacy technician attitudes toward burden screening in community pharmacies and assess caregiver burden in community pharmacies.
Descriptive cross-sectional study conducted in 10 community pharmacies in France. Pharmacists, pharmacy technicians and caregivers of patients with Alzheimer's disease were included in this study. Two self-reported questionnaires were used to explore attitudes of participants toward the burden screening in community pharmacy and to assess the caregiver burden in community pharmacy. The short version of the Zarit Burden Interview (range 0-7) was used for the burden screening.
Fifty-two pharmacists and pharmacy technicians, and 20 caregivers (61.8±13.7years) participated in this study. Seventy percent of caregivers and 96% of pharmacists/pharmacy technicians stated that caregiver burden screening should be conducted in community pharmacies. 65% of caregivers reported their caregiver status to their community pharmacist. Eighty-two percent of pharmacist/pharmacy technicians thought they had to inform the caregiver's general practitioners (GP) about the detected burden level. Of the 20 included caregivers, 18 had a perception of burden. The mean caregiver burden score detected in this exploratory study was 4.0±1.7, corresponding to a moderate to severe burden.
According to caregivers' opinion, community pharmacists and pharmacy technicians represent accessible health care professionals in primary care to quantify caregiver burden. The burden screening can be easily incorporated into clinical service offerings in community pharmacy practice. It provides a valuable opportunity to identify high-risk caregivers with the aim of referring them to their GP to prevent the caregiver's frailty.
探索社区药剂师、药剂师和药剂技术员对社区药剂中负担筛查的态度,并评估社区药剂中的照顾者负担。
在法国的 10 家社区药房进行描述性横断面研究。这项研究纳入了阿尔茨海默病患者的药剂师、药剂技术员和照顾者。使用两份自我报告问卷来探讨参与者对社区药房负担筛查的态度,以及评估社区药房中的照顾者负担。使用 Zarit 负担访谈简短版(范围 0-7)进行负担筛查。
本研究共纳入 52 名药剂师和药剂技术员,以及 20 名照顾者(61.8±13.7 岁)。70%的照顾者和 96%的药剂师/药剂技术员表示应在社区药房进行照顾者负担筛查。65%的照顾者向他们的社区药剂师报告了他们的照顾者身份。82%的药剂师/药剂技术员认为他们必须将检测到的负担水平告知照顾者的全科医生(GP)。在纳入的 20 名照顾者中,有 18 名有负担感。在这项探索性研究中检测到的照顾者负担平均得分为 4.0±1.7,对应于中度至重度负担。
根据照顾者的意见,社区药剂师和药剂技术员是初级保健中可及的医疗保健专业人员,可量化照顾者负担。负担筛查可以很容易地纳入社区药房实践中的临床服务提供中。它为识别高风险照顾者提供了有价值的机会,目的是将他们转介给他们的 GP,以防止照顾者的脆弱。